CLINICAL_TRIALS
trial_result
· 2016-05-12
Clinical Trial Update: Study of REGN1193 in Patients With Type 2 Diabetes Mellitus [Phase 1]
Summary
Phase 1 study of REGN1193 in patients with Type 2 diabetes mellitus has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: TERMINATED